Added to YB: 2026-08-27
Pitch date: 2026-08-25
QIA.DE [neutral]
Qiagen N.V.
-0.02%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Market Cap
$8.6B
Pitch Price
$43.37
Price Target
N/A
Dividend
6.61%
EV/EBITDA
12.36
P/E
21.24
EV/Sales
4.52
Sector
Life Sciences Tools and Services
Category
special_situation
QIAGEN (QIA Germany): New chief inherits a strategic review and a $225 million single-cell bet
QIA.DE (update): CEO transition + live strategic review = the setup. Jonathan Pratt (ex-Filtration Group CEO, Beckman Coulter/Waters/Pall life-sci tools background) named CEO eff 1-Sep-2026, succeeding Thierry Bernard; inherits $225M upfront Parse Biosciences single-cell deal he didn't sign, plus a Supervisory Board strategic review (advisors reportedly Moelis, Goldman) launched earlier 2026, weighing outcomes vs standalone plan — no timeline/preferred outcome disclosed; review could reshape ownership/structure before Pratt's tenure matures. Guidance reaffirmed: Q3 net sales +1-2% CER, adj EPS ≥$0.62; FY26 ~1-2% CER growth, adj EPS ≥$2.43. Thesis = optionality on review outcome atop low-single-digit organic growth; catalyst timing unknown.
Read full article (2 min)